Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1886

Enrollment

INDUSTRY

Sponsor class

Conditions

Menopause
Osteoporosis

Interventions

DRUG: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
DRUG: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
DRUG: bazedoxifene 20 mg
DRUG: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
DRUG: Placebo

Sponsor

Pfizer